Widespread molecular alterations present in stage I non-small cell lung carcinoma fail to predict tumor recurrence

Modern Pathology

Volumn 16, Issue 1, 2003, Pages 28-34

  Baksh, Fabien K ^a   Dacic, Sanja ^a   Finkelstein, Sydney D ^a,b   Swalsky, Patricia A ^a   Raja, Siva ^a   Sasatomi, Eizaburo ^a   Luketich, James D ^a   Fernando, Hiran C ^a   Yousem, Samuel A ^a  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Loss of heterozygosity; Non small cell lung carcinoma; Prognosis

Indexed keywords

ADULT; AGED; ALLELIC IMBALANCE; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; CLINICAL ARTICLE; DNA SEQUENCE; FEMALE; GENE MUTATION; GENETIC HETEROGENEITY; HETEROZYGOSITY LOSS; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MOLECULAR BIOLOGY; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; TUMOR RECURRENCE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; FEMALE; GENES, RAS; HUMANS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 0037260033     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000044621.08865.C4     Document Type: Article

References (45)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics 2000. CA Cancer J Clin 2000;50:7-33.
2. Pelletier MP, Edwardes MD, Michel RP, Halwani F, Morin JE. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. Can J Surg 2000;44:180-8.
3. Mountain CF. A new international staging system for lung cancer. Chest 1986;89:225S-33S.
4. Strauss GM, Kwiatkowski DJ, Harpole DH, Lynch TJ, Skarin AT, Sugarbaker DJ. Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol 1995;13:1265-79.
5. Flehinger BJ, Kimmel M, Melamed MR. The effect of surgical treatment on survival from early lung cancer: implications for screening. Chest 1992;101:1013-8.
6. Ichinose Y, Hara N, Ohta M, Yano T, Maeda K, Asoh H, et al. Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage 1 non-small-cell lung cancer? - a multivariate prognostic factor analysis of 151 patients. J Thorac Cardiovasc Surg 1993;106:90-4.
7. Harpole DH Jr, Herndon DH II, Wolfe WG, Iglehart D, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995;55: 51-6.
8. Harpole DH Jr, Richards WG, Herndon JE II, Sugarbaker DJ. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Annu Thorac Surg 1996;61:1470-6.
9. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990;323:561-5.
10. Mitsudomi T, Steinberg SM, Oie HK, Mulshine JL, Phelps R, Viallet J, et al. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991;51:4999-5002.
11. Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R, Shirakusa T. Mutation of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J Natl Cancer Inst 1993;85:2018-23.
12. Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993;53:1-4.
13. Tomizawa Y, Adachi J, Kohno T, Hamada K, Saito R, Noguchi M, et al. Prognostic significance of allelic imbalances on chromosome 9p in stage I non-small cell lung carcinoma. Clin Cancer Res 1999;5:1139-46.
14. Wistuba II, Behrens C, Virmani AK, Milchgrub S, Syed S, Lam S, et al. Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res 1999;59:1973-9.
15. Mitsudomi T, Oyama T, Nishida K, Ogami A, Osaki T, Sugio K, et al. Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clin Cancer Res 1996; 2:1185-9.
16. Rodenhuis S, Slebos R, Boot A, Evers S, Mooi W, Wagenaar S, et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 1988;48:5738-41.
17. Mitsudomi T, Oyama T, Nishida K, Ogami A, Osaki T, Nakanishi R, et al. p53 nuclear immunostaining and gene mutations in non-small cell lung cancer and their effect on patient survival. Annu Oncol 1995;10:9-13.
18. Virmani AK, Fong KM, Kodagoda D, McIntire D, Hung J, Tonk V, et al. Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer 1998;21:308-19.
19. Zhou X, Kemp BL, Khuri FR, Liu D, Lee JJ, Wu W, et al. Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer. Clin Can Res 2000;6: 559-65.
20. Fleming ID, Cooper JS, Henson DE, Hutter RP, Kennedy BJ, Murphy GP, et al., editors. AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven, 1997.
21. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, et al. Allelotype of colorectal carcinomas. Science 1989;244:217-21.
22. Sanchez-Cespedes M, Rosell R, Pifarre A, Lopez-Cabrerizo MP, Barnadas A, Sanchez JJ, et al. Microsatellite alterations at 5q21, 11p13, and 11p15.5 do not predict survival in non-small cell lung cancer. Clin Cancer Res 1997;3:1229-35.
23. Sanz-Ortega J, Bryant B, Sanz-Esponera J, Asenjo J, Saez MC, Torres A, et al. LOH at the APC/MCC gene (5q21) is frequent in early stages of non-small cell lung cancer. Pathol Res Pract 1999;195:677-80.
24. Fong KM, Zimmerman PV, Smith PJ. Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung cancer. Cancer Res 1995;55:220-3.
25. ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Can Res 1999;5:791-800.
26. Gregorio LD, Manenti G, Incarbone M, Pilotti S, Pastorino U, Pierotti MA, et al. Prognostic value of loss of heterozygosity and kras2 mutations in lung adenocarcinoma. Int J Cancer 1998;79:269-72.
27. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
28. Kohno H, Hiroshima K, Toyozaki T, Fujisawa T, Ohwada H. p53 mutation and allelic loss of chromosome 3p, 9p of preneoplastic lesions in patients with non-small cell lung carcinoma. Cancer 1999;85:341-7.
29. Li ZH, Zheng J, Weiss LM, Shibata D. c-K-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am J Pathol 1994;144:303-9.
30. Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD, et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999;18:643-50.
31. Tomizawa Y, Kohno T, Fujita T, Kiyama M, Saito R, Noguchi M, et al. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene 1999;18:1007-14.
32. Schiller JH, Adak S, Feins RH, Keller SM, Fry WA, Livingston RB, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of post-operative adjuvant therapy. J Clin Oncol 2001;19:448-57.
33. Lane DP. p53, guardian of the genome. Nature 1992;358: 15-6.
34. Fong KM, Kida Y, Zimmerman PV, Smith PJ. MYCL genotypes and loss of heterozygosity in non-small-cell lung cancer. Br J Cancer 1996;74:1975-8.
35. Gasparian AV, Laktionov KK, Belialova MS, Pirogova NA, Tatosyan AG, Zborovskaya IB. Allelic imbalance and instability of microsatellite loci on chromosome lp in human non-small-cell lung cancer. Br J Cancer 1998;77:1604-11.
36. Hosoe S, Ueno K, Shigedo Y, Tachibana I, Osaki T, Kumagai T, et al. A frequent deletion of chromosome 5q21 in advanced small cell and non-small cell carcinoma of the lung. Cancer Res 1994;54:1787-90.
37. Andre C, Hampe A, Lachaume P, Martin E, Wang XP, Manus V, et al. Sequence analysis of two genomic regions containing the KIT and the FMS receptor tyrosine kinase genes. Genomics 1997;39:216-26.
38. Nagai MA, Yamamoto L, Salaorni S, Pacheco MM, Brentani MM, Barbosa EM, et al. Detailed deletion mapping of chromosome segment 17q12-21 in sporadic breast tumors. Genes Chromosomes Cancer 1994;11:58-62.
39. Lu YJ, Dong XY, Shipley J, Zhang RG, Cheng SJ. Chromosome 3 imbalances are the most frequent aberration found in non-small cell lung carcinoma. Lung Cancer 1999;23:61-6.
40. Arai N, Morishita K, Shinmura K, Kohno T, Kim SR, Nohmi T, et al. Cloning of a human homolog of the yeast OGG1 gene that is involved in the repair of oxidative DNA damage. Oncogene 1997;14:2857-61.
41. Chevillard S, Radicella JP, Levalois C, Lebeau J, Poupon MF, Oudard S, et al. Mutations in OGG1, a gene involved in the repair of oxidative DNA damage, are found in human lung and kidney tumours. Oncogene 1998;16:3083-6.
42. Kohno T, Sato T, Takakura S, Takei K, Inoue K, Nishioka M, et al. Mutation and expression of the DCC gene in human lung cancer. Neoplasia 2000;2:300-5.
43. Shiseki M, Kohno T, Adachi J, Okazaki T, Otsuka T, Mizoguchi H, et al. Comparative allelotype of early and advanced stage non-small cell lung carcinomas. Genes Chromosomes Cancer 1996;17:71-7.
44. Shiseki M, Kohno T, Nishikawa R, Sameshima Y, Mizoguchi H, Yokota J. Frequent allelic losses on chromosomes 2q, 18q, and 22q in advanced non-small cell lung carcinoma. Cancer Res 1994;54:5643-8.
45. Takei K, Kohno T, Hamada K, Takita J, Noguchi M, Matsuno Y, et al. A novel tumor suppressor locus on chromosome 18q involved in the development of human lung cancer. Cancer Res 1998;58:3700-5.